title: [Osteogenetic capacity of cross-linked adjustable anti-tuberculosis drug sustained-release artificial composite].
abstract: OBJECTIVE
  To explore the osteogenetic capacity of cross-linked adjustable anti-tuberculosis drug sustained-release artificial composite (TPB/SA-RFP/PLA).
  
  
  METHODS
  The model of femur bone defect was established in rabbits.TPB/SA-RFP/PLA complex was implanted into defect parts in the experimental group while TPB/SA/PLA in the blank control group. At Weeks 4, 8 and 12, gross specimens received radiographic, histological and immunohistochemical examinations to determine the osteogenetic performance of TPB/SA-RFP/PLA.
  
  
  RESULTS
  As compared with the control group, TPB/SA-RFP/PLA complex had excellent osteogenic capacities while the TPB/SA/PLA group had no obvious osteogenic difference. Lane-sandhu histological and radiographic ratings demonstrated significant difference between TPB/SA-RFP/PLA (8.3 ± 0.3) and blank groups (2.2 ± 0.4) (P < 0.05). And TPB/SA/PLA showed no significant intragroup significance (P > 0.05). Two groups immunohistochemical Alkaline phosphatase was strongly positive in two test groups and weakly positive in the control group.
  
  
  CONCLUSIONS
  TPB/ SA-RFP/PLA has excellent profiles of bone conductivity and regeneration.And the incorporation of rifampin does not affect its osteogenetic capacity.
authors.affiliation: Department of Spinal Surgery, Second Military Medical College, Shanghai, China.
authors.forename: Yan-hai
authors.initials: YH
authors.lastname: Xi
authors.forename: Min-tao
authors.initials: MT
authors.lastname: Xue
authors.forename: Xiao-jian
authors.initials: XJ
authors.lastname: Ye
authors.forename: Ning
authors.initials: N
authors.lastname: Xu
authors.forename: Jin-tao
authors.initials: JT
authors.lastname: Qu
authors.forename: Xi-lin
authors.initials: XL
authors.lastname: Liu
authors.forename: Hai-long
authors.initials: HL
authors.lastname: He
mesh_terms: D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000494:pharmacology*; D001187:Artificial Organs; D001861:Bone Regeneration / Q000187:drug effects*; D003692:Delayed-Action Preparations; D049329:Nanostructures; D010012:Osteogenesis / Q000187:drug effects*; D011817:Rabbits; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology*; D023822:Tissue Engineering
chemical_list: D000904:Antibiotics, Antitubercular; D003692:Delayed-Action Preparations; D012293:Rifampin